A retrospective real‐world experience of immunotherapy in patients with extensive stage small‐cell lung cancer

Bibliographic Details
Title: A retrospective real‐world experience of immunotherapy in patients with extensive stage small‐cell lung cancer
Authors: Guihuan Qiu, Fei Wang, Xiaohong Xie, Ting Liu, Chen Zeng, Ziyao Chen, Maolin Zhou, Haiyi Deng, Yilin Yang, Xinqing Lin, Zhanhong Xie, Gengyun Sun, Chengzhi Zhou, Ming Liu
Source: Cancer Medicine, Vol 12, Iss 14, Pp 14881-14891 (2023)
Publisher Information: Wiley, 2023.
Publication Year: 2023
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: PD‐1/PD‐L1 inhibitor, prognosis, real‐world study, safety, small‐cell lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Abstract Background The treatment of extensive stage small‐cell lung cancer (ES‐SCLC) has only made modest progress in the past decade, with two immune checkpoint inhibitors (ICIs), atezolizumab and durvalumab, approved for the treatment of SCLC by January 2022. However, currently, there is limited real‐world data on ES‐SCLC patients received immunotherapy. Methods We retrospectively collected and analyzed the demographic and treatment data of ES‐SCLC patients at the First Affiliated Hospital of Guangzhou Medical University from January 2017 to January 2022. Survival and prognosis information was obtained through follow‐up. Results A total of 353 ES‐SCLC patients were included, of which 165 received immunotherapy combined with chemotherapy as the first‐line (FL) treatment (chemo‐immune group), and 188 received chemotherapy (chemotherapy group). The objective response rate (ORR) and disease control rate (DCR) of patients receiving immunotherapy as the FL treatment were better than the chemotherapy group (76.97% vs. 48.40%, p
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2045-7634
Relation: https://doaj.org/toc/2045-7634
DOI: 10.1002/cam4.5843
Access URL: https://doaj.org/article/7f927dc7876b44539095cd23ecd983c6
Accession Number: edsdoj.7f927dc7876b44539095cd23ecd983c6
Database: Directory of Open Access Journals
More Details
ISSN:20457634
DOI:10.1002/cam4.5843
Published in:Cancer Medicine
Language:English